Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia

D O'Connor, AV Moorman, R Wade… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Our aim was to determine the role of end-of-induction (EOI) minimal residual
disease (MRD) assessment in the identification and stratification of induction failure in …
被引用次数：83 相关文章

Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia

D O'Connor, AV Moorman, R Wade… - Journal of Clinical …, 2017 - pure.johnshopkins.edu
Purpose: Our aim was to determine the role of end-of-induction (EOI) minimal residual
disease (MRD) assessment in the identification and stratification of induction failure in …

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia

D O'Connor, AV Moorman, R Wade… - Journal of Clinical …, 2017 - discovery.ucl.ac.uk
PURPOSE: Our aim was to determine the role of end-of-induction (EOI) minimal residual
disease (MRD) assessment in the identification and stratification of induction failure in …

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia

D O'Connor, AV Moorman, R Wade… - Journal of Clinical …, 2017 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Our aim was to determine the role of
end-of-induction (EOI) minimal residual disease (MRD) assessment in the identification and …

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia

D O'Connor, AV Moorman, R Wade… - Journal of clinical …, 2017 - pubmed.ncbi.nlm.nih.gov
Purpose Our aim was to determine the role of end-of-induction (EOI) minimal residual
disease (MRD) assessment in the identification and stratification of induction failure in …
[PDF] archive.org

[PDF][PDF] Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia

D O'Connor, AV Moorman, R Wade, J Hancock… - J Clin …, 2017 - scholar.archive.org
Purpose Our aim was to determine the role of end-of-induction (EOI) minimal residual
disease (MRD) assessment in the identification and stratification of induction failure in …

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.

D O'Connor, A Moorman, R Wade, J Hancock… - Journal of Clinical …, 2017 - ora.ox.ac.uk
Purpose Our aim was to determine the role of end-of-induction (EOI) minimal residual
disease (MRD) assessment in the identification and stratification of induction failure in …
[PDF] academia.edu

[PDF][PDF] Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia

D O'Connor, AV Moorman, R Wade… - Journal of Clinical …, 2017 - academia.edu
Purpose Our aim was to determine the role of end-of-induction (EOI) minimal residual
disease (MRD) assessment in the identification and stratification of induction failure in …
[PDF] medpagetoday.com

[PDF][PDF] Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia

D O'Connor, AV Moorman, R Wade, J Hancock… - 2017 - clf1.medpagetoday.com
Purpose Our aim was to determine the role of end-of-induction (EOI) minimal residual
disease (MRD) assessment in the identification and stratification of induction failure in …

Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia

D O'Connor, AV Moorman, R Wade… - Journal of Clinical …, 2017 - eprints.ncl.ac.uk
Abstract© 2017 by American Society of Clinical Oncology. Purpose: Our aim was to
determine the role of end-of-induction (EOI) minimal residual disease (MRD) assessment in …